featured
Evaluating Minimal Residual Disease as an Intermediate Clinical Endpoint for Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma
Blood 2024 May 20;[EPub Ahead of Print], O Landgren, TJ Prior, T Masterson, C Heuck, OF Bueno, AB Dash, H Einsele, H Goldschmidt, S Knop, C Li, UH Mellqvist, I McFadden, C Oprea, JA Ross, M Talpes, J Hydren, J Ahlstrom, D Kazandjian, N Weinhold, R Zhang, M Stetler-Stevenson, GE Marti, SM DevlinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.